<DOC>
	<DOCNO>NCT03066687</DOCNO>
	<brief_summary>The primary purpose study evaluate effect food relative bioavailability single 9 milligram ( mg ) oral dose erdafitinib healthy participant .</brief_summary>
	<brief_title>A Study Determine Effect Food Pharmacokinetics Erdafitinib Healthy Participants</brief_title>
	<detailed_description />
	<criteria>Willing able adhere prohibition restriction specify protocol If woman , must childbearing potential : postmenopausal ( great [ &gt; ] 45 year age amenorrhea least 2 year , age amenorrhea least 12 month serum follicle stimulate hormone [ FSH ] &gt; 40 International Units Per Liter [ IU/L ] ) ; surgically sterile If woman , must negative serum betahuman chorionic gonadotropin ( hCG ) pregnancy test screen Day 1 Period 1 Period 2 If woman , must agree donate egg ( ovum , oocytes ) purpose assist reproduction study 3 month last study drug administration Body mass index ( BMI ; weight [ kg ] /height^2 [ ] ^2 ) 18 32 kilogram per square meter ( kg/m^2 ) ( inclusive ) , body weight less 50 kg Nonsmoker least 6 month first study drug administration History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , hepatic renal insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness investigator considers exclude participant could interfere interpretation study result History current evidence ophthalmic disorder , central serous retinopathy ( CSR ) retinal vein occlusion , active wet age relate macular degeneration , diabetic retinopathy macular edema , uncontrolled glaucoma , corneal pathology keratitis , keratoconjunctivitis , keratopathy , corneal abrasion , inflammation ulceration Clinically significant abnormal value hematology , serum chemistry , urinalysis screening deem appropriate investigator Clinically significant abnormal physical examination , vital sign , 12lead electrocardiogram ( ECG ) screening deem appropriate investigator Use prescription nonprescription medication ( include vitamin herbal supplement ) , except acetaminophen hormonal replacement therapy , within 14 day first dose study drug schedule completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>